Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q4 2025 Earnings Presentation
20 slides from Acadia Pharmaceuticals's earnings presentation, Feb 25, 2026
Slide 1: Fourth Quarter and Full Year 2025 Earnings Call
Fourth Quarter and Full Year 2025 Earnings Call February 25, 2026
Slide 2: Call Agenda
Call Agenda Welcome Financial Update Al Kildani Mark Schneyer Senior Vice President, IR and Corporate Communications Executive Vice President, Chief Financial Officer CEO Opening Remarks Closing Remarks Catherine Owen Adams Catherine Owen Adams Chief Executive Officer Chief Executive Officer Commerc
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams C H I E F E X E C U TI V E O F F I C E R 4
Slide 5: Fourth Quarter and Full Year Highlights
Fourth Quarter and Full Year Highlights R&D 4Q non-GAAP adjusted sales: 4Q sales: $110M (+13% YoY), Anticipating Phase 2 $189M (+17% YoY), driven by supported by broader U.S. Remlifanserin read-out in August- +13% volume growth and community uptake and steady October 2026 timeframe continued strong
Slide 6: Commercial Update
Commercial Update Tom Garner CHIEF COMMERCIAL OFFICER 6
Slide 7: NUPLAZID Updates
NUPLAZID Updates Quarterly Adjusted Annual Annual Adjusted Adjusted 800 Net Sales* Net Net Sales* Sales* $189M +17% 200 $189M $692M Q4 adjusted net sales* YoY growth +15% +17% $603M $162M 600 150 Increasing Demand: Field Force Impact: • +13% volume with • 30% field force expansion broad-based channe
Slide 8: DAYBUE Updates
DAYBUE Updates Quarterly Annual Net Sales Net Sales $110M 1,070 patients received shipment globally 120 $110M 400 $391M Q4 net sales $348M +12% $97M +13% 90 Strong Performance: Record Quarterly Uptake: 300 • Consistent fundamentals • Achieved the highest with strong persistency and global patient sh
Slide 9: DAYBUE STIX: A New Formulation Based on Rett Community Feedback
DAYBUE STIX: A New Formulation Based on Rett Community Feedback Powder for oral solution approved by U.S. FDA in December 2025, based on established safety and efficacy profile Differentiated features Early launch progress Incremental demand potential Mixes easily into beverages Strong early interes
Slide 10: R&D Update
R&D Update Elizabeth H.Z. Thompson E X E C U TI V E V I C E P R E S I D E N T | H E A D O F R E S E AR C H AN D D E V E L O P M E N T 10
Slide 11: Neurological and Rare Diseases Products and Pipeline
Neurological and Rare Diseases Products and Pipeline IND PROGRAM INDICATION MOLECULE DESCRIPTION DISCOVERY PHASE 1 PHASE 2 PHASE 3 LAUNCHED ENABLING Neurological diseases NUPLAZID® Parkinson's Disease Psychosis 5HT2A inverse agonist and antagonist Remlifanserin (ACP-204) Alzheimer's Disease Psychosi
Slide 12: Building Momentum Across Our Pipeline
Building Momentum Across Our Pipeline Recent Anticipated 8 Phase 2 1Q 26 Disclosed and multiple Initiation of ACP-211 in Initiate first-in-human study of Major Depressive Disorder ACP-271 in healthy volunteers undisclosed programs Phase 2 1Q 26 Initiation of remlifanserin (ACP-204) in Lewy Body Deme
Slide 13: EMA Regulatory Update
EMA Regulatory Update • Final CHMP opinion expected later this week following last month’s negative trend vote • Next steps contingent on the final opinion; currently plan to pursue re-examination process • Re-examination timeline ~120 days from adoption of opinion, with next CHMP opinion expected ~
Slide 14: Financial Update
Financial Update Mark Schneyer CHIEF FINANCIAL OFFICER 14
Slide 15: Non-GAAP Reconciliation
Non-GAAP Reconciliation YOY FY22 FY23 FY24 FY25 4Q24 4Q25 Change GAAP NUPLAZID Net Sales $517.2 $549.2 $609.4 $680.1 $162.9 $174.4 +7% Change in Estimate Recorded in Period - - - $20.1 - $15.2 Allocation of 2025 Amount ($1.4) ($3.8) ($6.6) ($8.3) ($1.7) ($1.0) Non-GAAP Adjusted NUPLAZID Net Sales $5
Slide 16: 4Q and FY 2025 GAAP Financial Highlights
4Q and FY 2025 GAAP Financial Highlights YoY YoY Millions, Except EPS 4Q25 4Q24 FY25 FY24 Change Change TOTAL Revenue $284.0 $259.6 9% $1,071.5 $957.8 12% NUPLAZID $174.4 $162.9 7% $680.1 $609.4 12% DAYBUE $109.6 $96.7 13% $391.4 $348.4 12% R&D $84.8 $100.7 -16% $328.8 $303.2 8% SG&A $155.6 $130.1 2
Slide 17: FY 2026 Financial Guidance
FY 2026 Financial Guidance FY25 Results FY26 GAAP Guidance NUPLAZID Net Sales $692 Million2 $760 to $790 Million NUPLAZID Gross-to-Net 24.6%2 22% to 24% DAYBUE Net Sales1 $391 Million $460 to $490 Million DAYBUE Gross-to-Net 22.3% 22% to 24% Total Revenue $1.07 Billion $1.22 to $1.28 Billion R&D Exp
Slide 18: Concluding Remarks
Concluding Remarks Catherine Owen Adams C H I E F E X E C U TI V E O F F I C E R 18
Slide 19: 2026-2027 Anticipated Milestones
2026-2027 Anticipated Milestones 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 CHMP Japan Phase 3 Trial Opinion TOP-LINE RESULTS Remlifanserin Phase 2 in (ACP-204) (ADP/LBDP) Alzheimer’s Disease Psychosis TOP-LINE RESULTS Other Pipeline ACP-271 ACP-711 ACP-211 Phase 2 Trial Programs Phase 1 in Phase 2 in Essent
Slide 20: Q&A Session
Q&A Session DO ACADIA 0
ACADIA Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix